ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1233 • ACR Convergence 2020

    Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA

    Jonathan Kay1, Amy Bock2, Noriko Iikuni3, Wuyan Zhang4 and Daniel Alvarez5, 1University of Massachusetts Medical School, Worcester, MA, 2Pfizer, Cambridge, MA, 3Pfizer, New York, NY, 4Pfizer, New York, 5Pfizer, Collegeville, PA

    Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
  • Abstract Number: 1445 • ACR Convergence 2020

    Citrulline Reactive B Cells Are Present in the Lungs of Risk RA and Early Untreated RA

    Vijay Joshua1, Malena Loberg-Haarhaus2, Akilan Krishnamurthy1, Meng Sun3, Christina Gerstner4, Aase Hensvold5, Khaled Amara1, Lena Israelsson1, Ragnhild Stålesen6, Bence Rethi7, Magnus Sköld7, Johan Grunewald1, Heidi Wähämaa1, Caroline Grönwall1, Vivianne Malmström8 and Anca Catrina5, 1Karolinska Institutet, Stockholm, Sweden, 2Rheumatology clinic, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 3Karolinska University Hospital and Karolinska Insitutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 6Karolinska Institute, Stockholm, Sweden, 7Karolinska Institutet, Stockholm, 8Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: Structural changes, increased tissue citrullination, signs of local inflammation and anti-citrullinated protein autoantibodies (ACPA) are present in the pulmonary compartment of early untreated seropositive…
  • Abstract Number: 1532 • ACR Convergence 2020

    The Non-psychotropic Phytocannabinoids Cannabigerol and Tetrahydrocannabinolic Acid Inhibit Rheumatoid Arthritis Synovial Fibroblast Function by Targeting the Wasabi Receptor TRPA1

    Torsten Lowin1, Matthias Schneider2 and Georg Pongratz3, 1Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Düsseldorf, Germany, 2Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany, 3Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, D�sseldorf, Germany

    Background/Purpose: While medical cannabis is available for german patients since 2017, its use to alleviate symptoms of rheumatic diseases is not recommended due to a…
  • Abstract Number: 1595 • ACR Convergence 2020

    Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making

    Joad Eseddi1, Puneet Bajaj2, Gabriela Schmajuk3, Jinoos Yazdany4 and Salahuddin Kazi5, 1UT Southwestern Medical Center, Dallas, TX, 2UT Southwestern, Dallas, TX, 3University of California, San Francisco, Atherton, CA, 4University of California, San Francisco, San Francisco, CA, 5Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Patient care is moving from physician directed treatment to a co-design framework that focuses on creating a partnership between patients and physicians. This new…
  • Abstract Number: 1718 • ACR Convergence 2020

    Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort

    Joanna Kedra1, David Hajage1, Alexandre Lafourcade1, Bernard Combe2, Maxime Dougados3 and Bruno Fautrel4, 1Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, 2University of Montpellier, Montpellier, France, 3Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, 4Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France

    Background/Purpose: Long-term observational studies on the prediction of structural damage progression (SDP) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely…
  • Abstract Number: 1734 • ACR Convergence 2020

    The Challenge of Assessing Wellbeing from the Patients` Perspective in Early Rheumatoid Arthritis

    Diederik De Cock1, Tianna Poffe2, Geert Verbeke2, Sofia Pazmino1, Veerle Stouten1, Delphine Bertrand1, Rene Westhovens3 and Patrick Verschueren4, 1KU Leuven, Leuven, Belgium, 2KU Leuven, Leuven, 3University Hospitals Leuven, Belgium, Leuven, Belgium, 4University Hospital Leuven, Leuven, Belgium

    Background/Purpose: Although more effective therapeutics and treatment strategies for Rheumatoid Arthritis (RA) have improved many patient-reported outcomes (PROs), still a sizeable number of patients in…
  • Abstract Number: 1752 • ACR Convergence 2020

    Prediction of Responder and Non-responder to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Pilot Study with Integrative Cluster Analysis

    Masanari Sugawara1, Yuichiro Fujieda2, Atsushi Noguchi3, Shun Tanimura4, Yuka Shimizu5, Ikuma Nakagawa6, Hiroki Takahashi7, Michihito Kono8, Masaru Kato2, Kenji Oku2, Olga Amengual2 and Tatsuya Atsumi9, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo city, Hokkaido, Japan, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 3Department of Internal Medicine and General Medicine, Japanese Red Cross Kitami Hospital, Sapporo, Japan, 4Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, Hokkaido, Japan, 53rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Sapporo, Japan, 6Department of Internal Medicine, Takikawa Municipal Hospital, Sapporo, Japan, 7Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, 8Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University, Sapporo, Japan, 9Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan

    Background/Purpose: [Background]Oral Janus kinase inhibitors (JAKi) show dramatical efficacy to reduce the disease activity in patients with rheumatoid arthritis (RA). However, there remain some patients who…
  • Abstract Number: 1781 • ACR Convergence 2020

    Pregnancy After Bariatric Surgery in Women with Rheumatic Diseases and Association with Adverse Birth Outcomes

    Namrata Singh1, Rebecca Baer2, Maya Swaminathan3, Shireesh Saurabh4, Jeffrey Sparks5, Gretchen Bandoli6, Elena Flowers7, Laura Jelliffe-Pawlowski2 and Kelli Ryckman8, 1University of Washington, Bellevue, WA, 2University of California San Francisco, San Francisco, 3University of Washington, Seattle, WA, 4Kaiser Permanente WA, Bellevue, WA, 5Brigham and Women's Hospital, Boston, MA, 6University of California San Diego, La Jolla, CA, 7UCSF, San Francisco, CA, 8University of Iowa, Iowa City

    Background/Purpose: Autoimmune rheumatic diseases (ARD) and bariatric surgery are each risk factors for adverse birth outcomes. To date, no study has investigated their combined impact…
  • Abstract Number: 1994 • ACR Convergence 2020

    Rheumatoid Arthritis Improvement After Exposure to an Anti-Inflammatory “ITIS” Diet Is Associated with Changes of Gut Microbiome and Systemic Metabolome

    Roxana Coras1, Cameron Martino2, Julia Gauglitz3, Anupriya Tripathi3, Alan Jarmusch4, Francesca Cedola5, Marta Fernandez Bustamante6, Meritxall Agustín-Perez7, Maram Alharthi8, Susan Lee8, Abha Singh8, Soo In Choi8, Tania Rivera8, Katherine Nguyen8, Tatyana Shekhtman9, Tiffany Holt10, Shahrokh Golshan11, Rob Knight3, Pieter Dorrestein12 and Monica Guma13, 1University of California San Diego, La Jolla, CA, 2Bioinformatics and Systems Biology, University of California San Diego, San Diego, 3University of California San Diego, San Diego, 4Univesity of California San Diego, San Diego, 5Hospital Policlinico Tor Vergata, Rome, Italy, 6Departement of Medicine, Division of Rheumatology, University of California San Diego, San Diego, 7Department of Medicine, University of California San Diego, San Diego, San Diego, 8Department of Medicine, Division of Rheumatology, University of California San Diego, San Diego, 9Department of Psychiatry, University of California, San Diego, San Diego, 10Center for Integrative Nutrition, University of California San Diego, San Diego, 11Department of Psychiatry, University of California San Diego, San Diego, CA, USA, San Diego, 12Department of Pharmacology and Pediatrics, University of California San Deigo, San Diego, 13Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA

    Background/Purpose: A new dimension has been added to the link between diet and health, the gut microbiome. Of particular interest is the influence of diet…
  • Abstract Number: 2011 • ACR Convergence 2020

    Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study

    Evgeny Nasonov1, Saeed Fatenejad2, Mariana Ivanova3, Diana Krechikova4, Sofia Kuzkina5, Alexey Maslyanskiy6, Tatiana Plaksina7, Mikhail Samsonov5, Marina Stanislav1, Tamara Tyabut8, Irina Vinogradova9, Sergey Yakushin10, Elena Zonova11 and Mark Genovese12, 1FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, 2SFC Medica, LLC, Charlotte, NC, 3UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, 4Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"”, Smolensk, Russia, 5JSC “R-Pharm”, Moscow, Russia, 6SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov", Saint Petersburg, Russia, 7SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", Nizhny Novgorod, Russia, 8Belarusian Medical Academy of Postgraduate Education, Minsk, Russia, 9Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia, 10Ryazan State Medical University, Ryazan, Russia, 11Novosibirsk State Medical University, State Clinical Polyclinic, Novosibirsk, Russia, 12Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…
  • Abstract Number: 0042 • ACR Convergence 2020

    Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity

    Rahaf Baker1, Jonathan Graf2, Laura Trupin2, Sarah Goglin3, Patricia Katz4, Jennifer Barton5, Jean Liew6 and Katherine Wysham7, 1Highland Hospital Internal Medicine, Oakland, CA, 2UCSF, San Francisco, CA, 3University of California San Francisco, Burlingame, CA, 4University of California, San Francisco, Novato, CA, 5VAPORHCS/OHSU, Portland, OR, 6University of Washington, Seattle, WA, 7VA Puget Sound/University of Washington, Seattle, WA

    Background/Purpose: Although management of RA has improved greatly over the past two decades with the advent of novel therapeutics, racial/ethnic and socioeconomic disparities persist. Traditional…
  • Abstract Number: 0131 • ACR Convergence 2020

    Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis

    Anahy María Brandy García1, Melania Martinez-Morillo2, Agueda Prior3, Rosa Serrano1, Lourdes Mateo4, Monica Guma5 and Laia Gifre2, 1Hospital Germans Trias i Pujol, Badalona, Spain, 2Hospital Germans Trias i Pujol, Barcelona, Spain, 3Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 4Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, 5University of California San Diego, La Jolla, CA

    Background/Purpose: Inflammatory arthritis in the elderly leads to greater comorbidity than that of the young patients, however, there are few data on body composition in…
  • Abstract Number: 0155 • ACR Convergence 2020

    Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry

    William Nowell1, Elaine Karis2, Kelly Gavigan3, Laura Stradford3, Scott Stryker2, Huifeng Yun4, Shilpa Venkatachalam5, Gregory Kricorian2, Lang Chen4, Hong Zhao6, Fenglong Xie6 and Jeffrey R Curtis4, 1Global Healthy Living Foundation, New York City, NY, 2Amgen Inc., Thousand Oaks, CA, 3Global Healthy Living Foundation, Upper Nyack, NY, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Global Healthy Living Foundation, Upper Nyack, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Methotrexate (MTX) is frequently used in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) because of its beneficial effects in both populations. Despite…
  • Abstract Number: 0189 • ACR Convergence 2020

    Determining the Relationship Between Mycobacterium Avium Subspecies Paratuberculosis Serostatus, Dietary Habits, Medication Regimen, and Joint Pain in Patients with Rheumatoid Arthritis

    Chelsea Guan1, Shazia Majid2, Sweta Chalise2, Saleh Naser2, Robert Sharp2 and Shazia Beg3, 1University of Central Florida, Orlando, FL, 2University of Central Florida, Orlando, 3University of Central Florida College of Medicine, Orlando

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that primarily affects synovial tissues. While the exact etiology is unknown, it is hypothesized that…
  • Abstract Number: 0206 • ACR Convergence 2020

    Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)

    Naoto Tamura1, Eiichi Tanaka2, Eisuke Inoue3, Yuri Yoshizawa4, Shigeru Matsumoto5, Hisashi Yamanaka6 and Masayoshi Harigai7, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, 2Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 3Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, 4Bristol-Myers Squibb K.K., Tokyo, Japan, 5Ono Pharmaceutical Co., Ltd., Tokyo, Japan, 6Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, 7Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…
  • « Previous Page
  • 1
  • …
  • 184
  • 185
  • 186
  • 187
  • 188
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology